Effects of a Milk-Based Meal Replacement Program on Weight and Metabolic Characteristics in Adults with Severe Obesity.

hypocaloric diet lifestyle modification milk obesity treatment type 2 diabetes

Journal

Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585

Informations de publication

Date de publication:
2020
Historique:
received: 07 08 2019
accepted: 15 11 2019
entrez: 12 3 2020
pubmed: 12 3 2020
medline: 12 3 2020
Statut: epublish

Résumé

Low energy meal replacement regimens can induce short-term weight loss in patients with severe obesity, but usually require specially formulated dietary supplements. We sought to determine the effects of a milk-based meal replacement program on anthropometric and metabolic characteristics in adults with severe obesity. We conducted a retrospective cohort study of patients attending our hospital-based bariatric medicine service who completed a 24-week program consisting of eight weeks of milk-based meal replacement followed by weight stabilisation and maintenance phases. Patients were seen fortnightly by the bariatric physician, nurse and dietitian. We assessed changes in anthropometric and metabolic outcomes in completers at 0, 8, 16 and 24 weeks. Of 105 program completers available for follow-up, 53.3% were female. Mean age was 51.1±11.2 years. Body weight decreased from 144.0±27.6 kg at baseline to 121.1±25.0 kg at 24 weeks ( These preliminary findings suggest that completion of a 24-week milk-based meal replacement program has large effects on important outcomes in adults with severe obesity. However, attrition was high. Prospective assessment of the efficacy, safety, durability and cost-effectiveness of this intervention seems warranted.

Identifiants

pubmed: 32158243
doi: 10.2147/DMSO.S226327
pii: 226327
pmc: PMC6986176
doi:

Types de publication

Journal Article

Langues

eng

Pagination

197-205

Informations de copyright

© 2020 Rafey et al.

Déclaration de conflit d'intérêts

MFR, CFM, RA, KK, HG, NB, PMO, CC, RM, MH and MO have no relevant conflicts to declare. CD and FMF have received honoraria, travel grants, unrestricted educational grants and served on advisory boards for Novo Nordisk, Eli Lilly, Pfizer Inc., Sanofi-Aventis, Astra Zeneca, Merck Sharp and Dohme, Boehringer Ingelheim, Janssen and Novartis. The authors report no other conflicts of interest in this work.

Références

Eur J Clin Nutr. 2013 Jul;67(7):759-64
pubmed: 23632752
Lancet. 2018 Feb 10;391(10120):541-551
pubmed: 29221645
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
BMJ. 2014 May 14;348:g2646
pubmed: 25134100
Diabetes Ther. 2018 Apr;9(2):613-621
pubmed: 29508274
J Clin Endocrinol Metab. 2008 Sep;93(9):3373-80
pubmed: 18583464
Eur Heart J. 2016 Oct 14;37(39):2999-3058
pubmed: 27567407
Am J Cardiol. 2005 Aug 1;96(3):399-404
pubmed: 16054467
J Nutr. 2015 Feb;145(2):246-52
pubmed: 25644344
Am J Clin Nutr. 2015 Feb;101(2):279-86
pubmed: 25646324
Am J Public Health. 2015 Sep;105(9):e54-9
pubmed: 26180980
J Am Diet Assoc. 2007 Oct;107(10):1755-67
pubmed: 17904936
Circulation. 1997 Oct 21;96(8):2520-5
pubmed: 9355888
Lancet Diabetes Endocrinol. 2016 Nov;4(11):913-921
pubmed: 27595918
Int J Obes (Lond). 2013 Jun;37(6):889-91
pubmed: 22986681
Br J Nutr. 2013 Oct;110(7):1178-87
pubmed: 23651522
Cochrane Database Syst Rev. 2014 Aug 08;(8):CD003641
pubmed: 25105982
Lancet Diabetes Endocrinol. 2014 Jun;2(6):474-80
pubmed: 24731674
Obesity (Silver Spring). 2006 Jul;14(7):1219-30
pubmed: 16899803
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Arch Intern Med. 2010 Jan 25;170(2):146-54
pubmed: 20101009
J Am Coll Nutr. 1999 Dec;18(6):620-7
pubmed: 10613414
Clin Obes. 2011 Feb;1(1):31-40
pubmed: 25586973
Eur J Nutr. 2016 Jun;55(4):1389-96
pubmed: 26099369
Br J Nutr. 2014 Aug 28;112(4):513-9
pubmed: 24870967
Br J Nutr. 2013 Aug 28;110(3):413-9
pubmed: 23286782
Ann Intern Med. 2005 Nov 1;143(9):659-72
pubmed: 16263889
BMC Endocr Disord. 2015 Aug 01;15:37
pubmed: 26231181
Am J Clin Nutr. 2007 Aug;86(2):301-7
pubmed: 17684198
Clin Obes. 2014 Oct;4(5):254-66
pubmed: 25825858
Obesity (Silver Spring). 2014 Sep;22(9):1942-51
pubmed: 24962106
Nutr Res. 2014 Oct;34(10):856-61
pubmed: 25277886
Postgrad Med J. 1975 Jul;51(597):441-5
pubmed: 810782

Auteurs

Mohammed F Rafey (MF)

Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland.
HRB Clinical Research Facility, National University of Ireland, Galway, Ireland.

Conor F Murphy (CF)

Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland.
HRB Clinical Research Facility, National University of Ireland, Galway, Ireland.

Razk Abdalgwad (R)

Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland.
HRB Clinical Research Facility, National University of Ireland, Galway, Ireland.

Katriona Kilkelly (K)

Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland.

Helena Griffin (H)

Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland.

Niamh Beatty (N)

Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland.

Paula M O'Shea (PM)

Department of Clinical Biochemistry, Galway University Hospitals, Galway, Ireland.

Chris Collins (C)

HRB Clinical Research Facility, National University of Ireland, Galway, Ireland.
Department of Surgery, Galway University Hospitals, Galway, Ireland.

Robert McGrath (R)

Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland.

Mary Hynes (M)

Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland.

Colin Davenport (C)

Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland.
HRB Clinical Research Facility, National University of Ireland, Galway, Ireland.

Martin O'Donnell (M)

HRB Clinical Research Facility, National University of Ireland, Galway, Ireland.

Francis M Finucane (FM)

Bariatric Medicine Service, Centre for Diabetes, Endocrinology and Metabolism, Galway University Hospitals, Galway, Ireland.
HRB Clinical Research Facility, National University of Ireland, Galway, Ireland.

Classifications MeSH